The British genetics company will use the proceeds to support the roll out of its Alzheimer's disease testing service.
Two new studies have delivered a multitude of new markers linked to testicular cancer, as well as a better understanding of the genetic architecture of the disease.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
In PNAS this week: high-altitude adaptation signature among Tibetans, de novo mutations in early-onset high myopia, and more.
The proceeds from the seed round will enable the company to fund the development and commercial launch of a $15 genomic test for dairy and beef cattle.
The researchers believe that by monitoring mtDNA copy number in blood, they will be able to identify people at risk for developing CHD who could benefit from preventative efforts.
Researchers analyzed the exomes of metastatic tumor samples from patients who died of breast cancer to piece together the genomic evolution.
Illumina and the H3Africa Consortium hope the array will allow future GWAS to address African genomic diversity in a way that previous chips have not.
Researchers working on the Human Functional Genomics Project have begun to unravel genetic relationships and variations in human immune response.
The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.